Moderna and Laboratorios Farmacéuticos Rovi are collaborating on a large-scale, commercial fill-finish manufacturing of Moderna’s mRNA vaccine candidate against COVID-19 (mRNA-1273) at ROVI’s facility in Madrid, Spain.
As part of the agreement, ROVI will provide vial filling and packaging capacity by procuring a new production line and equipment for compounding, filling, automatic visual inspection and labelling to support production of hundreds of millions of doses of the vaccine candidate intended in principle to supply markets outside of the U.S. starting in early 2021.
ROVI will also hire additional staffing required to support manufacturing operations and production.
Juan Andres, Moderna’s Chief Technology Operations and Quality Officer, said: “ROVI’s experience as a global manufacturer of drug product and expertise in fill-finish will be an important partnership for us to establish dedicated supply chains that can meet the needs of different countries and regions.”
This latest announcement follows an earlier agreement between Moderna and Catalent. Under that agreement, Catalent will provide large-scale, commercial fill-finish manufcturing for Moderna’s COVID-19 vaccine candidate (mRNA-1273) at it biologics facility in Bloomington, Indiana.